June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
OSPREY trial: randomized, active-controlled, phase II study to evaluate safety and efficacy of RTH258, a humanized single-chain anti-VEGF antibody fragment, in patients with neovascular AMD
Author Affiliations & Notes
  • Lawrence J Singerman
    Retina Associates of Cleveland, Cleveland, OH
  • Andreas Weichselberger
    Novartis Pharma, Basel, Switzerland
  • Peter Sallstig
    Alcon Research Ltd., Fort Worth, TX
  • Footnotes
    Commercial Relationships Lawrence Singerman, Alcon Laboratories (E); Andreas Weichselberger, Novartis Pharma (E); Peter Sallstig, Alcon Laboratories (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 4801. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Lawrence J Singerman, Andreas Weichselberger, Peter Sallstig; OSPREY trial: randomized, active-controlled, phase II study to evaluate safety and efficacy of RTH258, a humanized single-chain anti-VEGF antibody fragment, in patients with neovascular AMD. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):4801.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

RTH258 is a humanized single-chain antibody fragment that inhibits vascular endothelial growth factor (VEGF), binding with high affinity to all VEGF-A isoforms. RTH258 weighs 26kDa and is significantly smaller than currently available anti-VEGF treatment options. This smaller size may facilitate increased penetration of ocular tissues and reduced systemic exposure. It also allows for delivery of a higher molar dose within a 50µl volume. The OSPREY trial (NCT01796964) was designed to evaluate the safety and efficacy of repeat doses of RTH258 versus aflibercept in patients with neovascular age-related macular degeneration (nAMD).

 
Methods
 

The OSPREY trial was a randomized, double-masked, active-controlled study of 56 weeks’ duration, designed to test the hypothesis of non-inferiority of RTH258 to aflibercept at weeks 12 and 16. Subjects with untreated active choroidal neovascularization due to AMD were randomized 1:1 to RTH258 or aflibercept.

 
Results
 

The Full Analysis Set included 89 patients. Mean age was 78.0 years (range 55.0-96.0 years); 59.6% of subjects were female; 78.7% of subjects had unilateral AMD; mean best-corrected visual acuity was 54.8 ETDRS letters; mean central subfield thickness was 492.9 μm; 33.7% of subjects had intraocular hemorrhage; 84.3% of subjects had hyperreflective material; 89.9% of subjects had subretinal fluid; and 85.4% of patients had intraretinal fluid cystoid edema. Demographic and baseline ocular characteristics are presented in Table 1. Non-inferiority was met, and RTH258 was well tolerated.

 
Conclusions
 

The OSPREY trial results support the further development of RTH258. The visual and anatomical outcomes, combined with the data on durability, highlight the potential role of RTH258 in the management of nAMD.  

 
Table 1 OSPREY (C-12-006) Subject Demographics and Baseline Ocular Characteristics
 
Table 1 OSPREY (C-12-006) Subject Demographics and Baseline Ocular Characteristics

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×